Follicular Lymphoma Treatment Market to Grow at 8.1% CAGR from 2025-2029
The Business Research Company
The Business Research Company's Follicular Lymphoma Treatment Global Market Report 2025 – Market Size, Trends, And Global Forecast 2025-2034
LONDON, GREATER LONDON, UNITED KINGDOM, November 24, 2025 /EINPresswire.com/ -- What Is The Follicular Lymphoma Treatment Market Size And Growth?
The follicular lymphoma treatment market size has seen significant growth in the past few years. It's projected that it will expand from $3.05 billion in 2024 to $3.28 billion in 2025, with a compound annual growth rate (CAGR) of 7.5%. The escalation in the historic period is linked to the elevated prevalence of follicular lymphoma, advancements in cancer diagnostic techniques, growth of the aging population, progress in clinical research and drug development, as well as partnerships in oncology research.
The market for follicular lymphoma treatment is slated to witness robust growth in the upcoming years. It is expected to reach a value of $4.49 billion by 2029, growing at a CAGR of 8.1%. The projected growth in the forthcoming period can be accredited to approaches in personalized medicine, advancements in immunotherapy, increase in availability of innovative treatments, emphasis on the quality of life, and worldwide oncology cooperation initiatives. The major trends predicted to influence the forecast period consist of clinical studies and research efforts, insights into epigenetic modifiers, upliftment in radioimmunotherapy, implementation of artificial intelligence (AI), and worldwide partnership for treatment accessibility.
Download a free sample of the follicular lymphoma treatment market report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=10758&type=smp
What Are The Current Leading Growth Drivers For Follicular Lymphoma Treatment Market?
The escalating occurrence of follicular lymphoma is predicted to fuel the expansion of the market for follicular lymphoma treatments in the future. The occurrence of follicular lymphoma relates to the aggregate quantity or fraction of individuals diagnosed with follicular lymphoma within a distinct demographic, either at a specific point in time or over a fixed interval. Factors leading to this progression include an aging populace, genetic susceptibility, advancements in diagnostic methodologies, as well as amplified awareness and screening procedures. Treatment for follicular lymphoma curtails its frequency by intervening at various disease phases, thus assisting in the management and progression of the disease. The upward trend in follicular lymphoma incidents is stimulating the evolution of the follicular lymphoma therapeutic market. As reported by the American Cancer Society, a voluntary organization based in the U.S., in January 2023, non-Hodgkin lymphoma, a form of indolent follicular lymphoma, holds the majority share of all types of cancer in the U.S., making up about 4% of the total. The Society forecasts that approximately 80,550 individuals (comprising 44,880 men and 35,670 women) will be diagnosed with NHL, including both adults and children. Therefore, the accelerating occurrence of follicular lymphoma is spearheading the growth of the market for follicular lymphoma treatments.
Which Companies Are Currently Leading In The Follicular Lymphoma Treatment Market?
Major players in the Follicular Lymphoma Treatment include:
• AbbVie Inc.
• Bayer AG
• Bristol Myers Squibb Company
• F. Hoffmann-La Roche Ltd.
• Johnson and Johnson Services Inc.
• GlaxoSmithKline plc
• Novartis AG
• Merck & Co. Inc.
• EpiZyme Inc.
• Boehringer Ingelheim GmbH
What Are The Main Trends, Positively Impacting The Growth Of Follicular Lymphoma Treatment Market?
Developments in technology for the diagnosis and treatment of follicular lymphoma are an emerging trend offering opportunities in the follicular lymphoma treatment market. In an effort to remain competitive, companies in the market are adopting these, advanced methodologies. For example, in December 2022, the United States biotech firm Genentech Inc. obtained FDA approval for Lunsumio, an innovative bispecific antibody developed for the treatment of relapsed or refractory follicular lymphoma. This antibody represents a new generation of fixed-duration cancer treatment immunotherapies, and it is immediately available, eliminating the need for patients to wait to start treatment. The FDA approved this based on the favourable outcomes of the Lunsumio Phase II GO29781 study involving patients with heavily pretreated FL, particularly those at high risk of disease progression or those who failed to respond to previous treatments.
How Is The Follicular Lymphoma Treatment Market Segmented?
The follicular lymphoma treatment market covered in this report is segmented –
1) By Treatment: Monoclonal Antibodies, Targeted Therapy, Chemotherapy, Radiation Therapy, Stem Cell Transplant, Alkylating Agents, Nucleoside Analogues, Anthracycline Derivatives, Other Treatments
2) By Product Type: Tablets, Capsules, Injectables, Other Product Types
3) By Route of Administration: Oral, Parenteral, Other Route of Administration
4) By End Use: Hospitals, Oncology Centers, Ambulatory Care Centers, Academic Research Institutes, Other End Users
Subsegments:
1) By Monoclonal Antibodies: Rituximab, Obinutuzumab, Ofatumumab
2) By Targeted Therapy: PI3K Inhibitors, BTK Inhibitors, BCL-2 Inhibitors
3) By Chemotherapy: CHOP Regimen, Bendamustine, Fludarabine
4) By Radiation Therapy: External Beam Radiation Therapy (EBRT), Radioimmunotherapy
5) By Stem Cell Transplant: Autologous Stem Cell Transplant, Allogeneic Stem Cell Transplant
6) By Alkylating Agents: Cyclophosphamide, Ifosfamide
View the full follicular lymphoma treatment market report:
https://www.thebusinessresearchcompany.com/report/follicular-lymphoma-treatment-global-market-report
Which Is The Dominating Region For The Follicular Lymphoma Treatment Market?
In 2024, North America stood as the leading region in the follicular lymphoma treatment market, with projected growth prospects. The geographical areas analyzed in the report on the follicular lymphoma treatment market include Asia-Pacific, Western Europe, Eastern Europe, South America, the Middle East, and Africa.
Browse Through More Reports Similar to the Global Follicular Lymphoma Treatment Market 2025, By The Business Research Company
Ent Devices Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/ent-devices-global-market-report
Nasal Splints Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/nasal-splints-global-market-report
Cough And Cold Preparations Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/cough-and-cold-preparations-global-market-report
Speak With Our Expert:
Saumya Sahay
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: saumyas@tbrc.info
The Business Research Company - www.thebusinessresearchcompany.com
Follow Us On:
• LinkedIn: https://in.linkedin.com/company/the-business-research-company
Oliver Guirdham
The Business Research Company
+44 7882 955267
info@tbrc.info
Visit us on social media:
LinkedIn
Facebook
X
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
